Pharmacologic Therapies Across the Continuum of Left Ventricular Dysfunction

American Journal of Cardiology

Volumn 102, Issue 5 SUPPL., 2008, Pages 21G-28G

  Abraham, William T ^a   Greenberg, Barry H ^b   Yancy, Clyde W ^c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENALAPRIL; EPLERENONE; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; LOSARTAN; METOPROLOL; MILRINONE; NAXIFYLLINE; NITROPRUSSIDE SODIUM; PLACEBO; PROPRANOLOL; RAMIPRIL; SPIRONOLACTONE; TIMOLOL; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN;

ANGIOPLASTY; ARTICLE; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HORMONAL REGULATION; HUMAN; HYPERKALEMIA; MORTALITY; PRIORITY JOURNAL; RADIOISOTOPE VENTRICULOGRAPHY; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL; TREATMENT OUTCOME;

EID: 50949130399     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.06.007     Document Type: Article

References (47)

1. Hunt S.A. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 46 (2005) e1-e82
2. Goldberg L.R., and Jessup M. Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 113 (2006) 2851-2860
3. Sigurdsson A., Held P., and Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 126 (1993) 1068-1076
4. Williams R.E. The effect of neurohormonal antagonists in reducing heart failure hospitalizations. Curr Med Res Opin 22 (2006) 139-150
5. 2 receptors in postinfarcted hypertrophied myocytes and stretch-mediated apoptotic cell death. Am J Pathol 156 (2000) 1663-1672
6. Delcayre C., and Swynghedauw B. Molecular mechanisms of myocardial remodeling: the role of aldosterone. J Mol Cell Cardiol 34 (2002) 1577-1584
7. Rocha R., Rudolph A.E., Frierdich G.E., Nachowiak D.A., Kekec B.K., Blomme E.A., McMahon E.G., and Delyani J.A. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 (2002) H1802-H1810
8. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., Simon A.B., and Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 (1984) 819-823
9. Mann D.L., Kent R.L., Parsons B., and Cooper IV G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85 (1992) 790-804
10. Køber L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D.S., Auclert L., Pauly N.C., and Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
11. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
12. Pfeffer M.A., Braunwald E., Moý L.A., Basta L., Brown Jr. E.J., Cuddy T.E., Davis B.R., Geltman E.M., Goldman S., Flaker G.C., et al., SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
14. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J.V., Michelson E.L., Olofsson B., s̈tergren J., Yusuf S., and CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
15. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
16. Flather M.D., Yusuf S., Køber L., Pfeffer M., Hall A., Murray G., Torp-Pedersen C., Ball S., Pogue J., Moyé L.A., Braunwald E., and ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355 (2000) 1575-1581
17. Ray S.G., Pye M., Oldroyd K.G., Christie J., Connelly D.T., Northridge D.B., Ford I., Morton J.J., Dargie H.J., and Cobbe S.M. Early treatment with captopril after acute myocardial infarction. Br Heart J 69 (1993) 215-222
18. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351 (2004) 2058-2068
19. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Køber L., Maggioni A.P., Solomon S.D., Swedberg K., Van de Werf F., White H., et al., Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
20. Dickstein K., and Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360 (2002) 752-760
21. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (1981) 801-807
22. β-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247 (1982) 1707-1714
23. Hjalmarson A., Herlitz J., Holmberg S., Ryden L., Swedberg K., Vedin A., Waagstein F., Waldenstrom A., Waldenstrom J., Wedel H., Wilhelmsen L., and Wilhelmsson C. The Göteborg Metoprolol Trial: effects on mortality and morbidity in acute myocardial infarction. Circulation 67 (1983) I26-I32
24. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
25. Packer M., Bristow M.R., Cohn J.N., Colucci W.S., Fowler M.B., Gilbert E.M., Shusterman N.H., for the U.S., and Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
26. The CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
27. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
28. Packer M., Coats A.J.S., Fowler M.B., Katus H.A., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Roecker E.B., Schultz M.K., DeMets D.L., and Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
29. Philippides G.J. Managing the post-myocardial infarction patient with asymptomatic left ventricular dysfunction. Cardiology 105 (2006) 95-107
30. Doughty R.N., Whalley G.A., Walsh H.A., Gamble G.D., Lṕez-Sendń J., Sharpe N., and CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 109 (2004) 201-206
31. Gottlieb S.S., McCarter R.J., and Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339 (1998) 489-497
32. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., and Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
33. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., Bittman R., Hurley S., Kleiman J., Gatlin M., and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
34. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1622-1632
35. Latini R., Masson S., Anand I., Salio M., Hester A., Judd D., Barlera S., Maggioni A.P., Tognoni G., and Cohn J.N. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 25 (2004) 292-299
36. Givertz M.M., and Braunwald E. Neurohormones in heart failure: predicting outcomes, optimizing care. Eur Heart J 25 (2004) 281-282
37. Richards A.M., Doughty R., Nicholls M.G., Macmahon S., Ikram H., Sharpe N., Espiner E.A., Frampton C., Yandle T.G., and Australia-New Zealand Heart Failure Group. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 99 (1999) 786-792
38. Fonarow G.C., and Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 9 (2004) 179-185
39. Fonarow G.C. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 3 suppl 4 (2002) S18-S27
40. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12 (2006) 10-38
41. 1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
42. Lee C.R., Watkins M.L., Patterson J.H., Gattis W., O'Connor C.M., Gheorghiade M., and Adams Jr. K.F. Vasopressin: a new target for the treatment of heart failure. Am Heart J 146 (2003) 9-18
43. Gheorghiade M., Gattis W.A., O'Connor C.M., Adams Jr. K.F., Elkayam U., Barbagelata A., Ghali J.K., Benza R.L., McGrew F.A., Klapholz M., Ouyang J., Orlandi C., and ACTIV in CHF Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004) 1963-1971
44. Colucci W.S., Elkayam U., Horton D.P., Abraham W.T., Bourge R.C., Johnson A.D., Wagoner L.E., Givertz M.M., Liang C.S., Neibaur M., Haught W.H., LeJemtel T.H., and Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 343 (2000) 246-253
45. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
46. Sackner-Bernstein J.D., Kowalski M., Fox M., and Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
47. Cleland J.G., Coletta A.P., and Clark A.L. Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur J Heart Fail 8 (2006) 764-766